Research graph
References from Diagnostic pitfalls in site-of-origin immunohistochemistry for metastatic carcinoma: Aberrant expression and loss of lineage-associated markers. Local targets link to admitted publications; unresolved targets remain external evidence.
Real-world histopathological approach to malignancy of undefined primary origin (MUO) to diagnose cancers of unknown primary (CUPs)
10.1007/s00428-022-03435-z · 2023 · External reference
Updates on utility of immunohistochemistry in diagnosis of metastatic breast cancer
10.1016/j.humpath.2025.105821 · 2025 · External reference
Diagnosis of metastatic neoplasms: a Clinicopathologic and morphologic approach
10.5858/134.2.194 · 2010 · External reference
Trichorhinophalangeal syndrome type 1 (TRPS1) in breast pathology: diagnostic utility and pitfalls
10.1186/s13000-025-01623-4 · 2025 · External reference
Framework for the pathology workup of metastatic castration-resistant prostate Cancer biopsies
10.1158/1078-0432.ccr-24-2061 · 2025 · External reference
Review of immunohistochemistry techniques: applications, current status, and future perspectives
10.1053/j.semdp.2024.05.001 · 2024 · External reference
The transcriptional and epigenetic landscape of Cancer cell lineage plasticity
10.1158/2159-8290.cd-23-0225 · 2023 · External reference
Cancer cell plasticity during tumor progression, metastasis and response to therapy
2023 · External reference
Prostate cancer cells converge to an inflammatory-like state upon metastatic dissemination
10.1038/s41467-025-67856-5 · 2025 · External reference
Progressive plasticity during colorectal cancer metastasis
10.1038/s41586-024-08150-0 · 2025 · External reference
ASCL1 activates neuronal stem cell-like lineage programming through remodeling of the chromatin landscape in prostate cancer
10.1038/s41467-022-29963-5 · 2022 · External reference
PAX8 expression in cancerous and non-neoplastic tissue: a tissue microarray study on more than 17,000 tumors from 149 different tumor entities
10.1007/s00428-024-03872-y · 2024 · External reference
Polyclonal PAX8 expression in carcinomas of the biliary tract — frequent non-specific staining represents a potential diagnostic pitfall
10.1016/j.anndiagpath.2021.151762 · 2021 · External reference
Evaluation of breast-specific marker expression in metastatic breast cancers: correlation with subtype switch
10.1111/his.15358 · 2025 · External reference
TRPS1, GATA3, and SOX10 expression in triple-negative breast carcinoma
10.1016/j.humpath.2022.04.006 · 2022 · External reference
TRPS1 is a highly sensitive marker for breast Cancer: a tissue microarray study evaluating more than 19,000 tumors from 152 different tumor entities
10.1097/pas.0000000000002213 · 2024 · External reference
Immunohistochemical evaluation of GATA3 expression in tumors and Normal tissues
10.1309/ajcp5uafmsa9zqbz · 2012 · External reference
Sox10—a marker for not only Schwannian and melanocytic neoplasms but also myoepithelial cell tumors of soft tissue: a systematic analysis of 5134 tumors
10.1097/pas.0000000000000398 · 2015 · External reference
TTF-1 is a highly sensitive but not fully specific marker for pulmonary and thyroidal cancer: a tissue microarray study evaluating more than 17,000 tumors from 152 different tumor entities
10.1007/s00428-024-03926-1 · 2024 · External reference
Napsin a expression in human tumors and Normal tissues
10.3389/pore.2021.613099 · 2021 · External reference
Immunohistochemical TTF-1 and napsin a expression in gastrointestinal adenocarcinomas—low frequency but an important pitfall
2025 · External reference
The utility of the lineage specific immunohistochemical stains SATB2, CDX2, and villin, and the mucin glycoproteins MUC2, MUC5AC, and MUC6 to distinguish pulmonary invasive mucinous adenocarcinoma from metastatic colorectal carcinoma
10.1016/j.humpath.2024.105627 · 2024 · External reference
Use of SATB2 and CDX2 immunohistochemistry to characterize and diagnose colorectal Cancer
10.1097/pai.0000000000001216 · 2024 · External reference
Performance of different prostate specific antibodies in the cytological diagnosis of metastatic prostate adenocarcinoma
10.1002/dc.23809 · 2017 · External reference
Cytomorphology, immunoprofile, and clinicopathologic correlation of metastatic prostatic carcinoma
10.1016/j.humpath.2022.10.007 · 2022 · External reference
NKX3.1 as a marker of prostatic origin in metastatic tumors
10.1097/pas.0b013e3181e6cbf3 · 2010 · External reference
The utility of PSMA and PSA immunohistochemistry in the cytologic diagnosis of metastatic prostate carcinoma
10.1002/dc.23075 · 2014 · External reference
PAX-8 expression in renal tumours and distant sites: a useful marker of primary and metastatic renal cell carcinoma?
10.1136/jclinpath-2014-202259 · 2015 · External reference
Reliability of PAX8 in clinical practice to accurately determine primary site of origin in female pelvic or abdominal lesions
10.1016/j.anndiagpath.2014.04.001 · 2014 · External reference
TRPS1 is a promising marker for all subtypes of breast cancer
10.1111/his.15126 · 2024 · External reference
Concomitant expression patterns of CDX2 and SATB2 as prognostic factors in stage III colorectal cancers
10.1016/j.anndiagpath.2024.152289 · 2024 · External reference
CDX2 and SATB2 loss are associated with myeloid cell infiltration and poor survival in colorectal cancer
10.1007/s00262-025-03964-x · 2025 · External reference
Neuroendocrine differentiation of prostate cancer leads to PSMA suppression
10.1530/erc-18-0226 · 2019 · External reference
Carcinoma of unknown primary (CUP): an update for histopathologists
10.1007/s10555-023-10101-6 · 2023 · External reference
Principles of analytic validation of Immunohistochemical assays: guideline update
10.5858/arpa.2023-0483-cp · 2024 · External reference
Effect of decalcification protocols on immunohistochemistry and molecular analyses of bone samples
10.1038/s41379-020-0503-6 · 2020 · External reference
Belgian recommendations for analytical verification and validation of Immunohistochemical tests in laboratories of anatomic pathology
10.1097/pai.0000000000001165 · 2024 · External reference
Cancer of unknown primary: ESMO clinical practice guideline for diagnosis, treatment and follow-up
10.1016/j.annonc.2022.11.013 · 2023 · External reference
Tri-layer microbiology for LMIC hospitals: linking syndromic panels with reflex culture and targeted sequencing for real world care - a narrative review
10.1016/j.bjid.2026.105808 · 2026 · External reference
Methylation-sensitive LAMP (MS-LAMP): assay design, readouts, and clinical translation in microbiology
10.1016/j.mimet.2026.107520 · 2026 · External reference
A comparison of DNA sequencing and gene expression profiling to assist tissue of origin diagnosis in cancer of unknown primary
10.1002/path.6022 · 2023 · External reference
Randomized phase II trial comparing site-specific treatment based on gene expression profiling with carboplatin and paclitaxel for patients with cancer of unknown primary site
10.1200/jco.18.00771 · 2019 · External reference
Site-specific therapy guided by a 90-gene expression assay versus empirical chemotherapy in patients with cancer of unknown primary (Fudan CUP-001): a randomised controlled trial
10.1016/s1470-2045(24)00313-9 · 2024 · External reference
SEOM-GECOD clinical guideline for cancer of unknown primary (update 2025)
10.1007/s12094-026-04241-8 · 2026 · External reference
A phase III trial of empiric chemotherapy with cisplatin and gemcitabine or systemic treatment tailored by molecular gene expression analysis in patients with carcinomas of an unknown primary (CUP) site (GEFCAPI 04)
10.1093/annonc/mdz394 · 2019 · External reference
Unresolved reference
2025 · External reference
Molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary (CUPISCO): an open-label, randomised, phase 2 study
10.1016/s0140-6736(24)00814-6 · 2024 · External reference
